Persistent damage to *Enterocytozoon bieneusi*, with persistent symptomatic relief, after combined furazolidone and albendazole in AIDS patients

D Dionisio, L Ibba Manneschi, S Di Lollo, A Orsi, G Sterrantino, F Leoncini, M Pozzi, M A Vinattieri, A Tani, A Papucci

**Abstract**

**Aim**—To investigate morphological changes in *Enterocytozoon bieneusi* and the duration of symptomatic relief after combination treatment with furazolidone and albendazole in AIDS patients.

**Methods**—Four severely immunocompromised AIDS patients with symptomatic *E. bieneusi* infection of the gut received an 18 day course of combined furazolidone and albendazole (500 + 800 mg daily). All patients were monitored for parasite shedding in stool by light microscopy at the end of treatment and monthly during follow up. At the end of treatment, duodenal biopsy specimens obtained from three patients were studied by transmission electron microscopy by two pathologists blind to the patients' treatment or clinical outcome. Duodenal biopsy specimens obtained from one of the patients two months after completion of treatment were also studied electronmicroscopically.

**Results**—All patients had long lasting symptomatic relief, with a major decrease—or transient absence—of spore shedding in stools from completion of treatment. After treatment, changes in the parasite were described after treatment.1 3–5

Recently we reported both symptomatic relief and light and electron microscopic changes in *E. bieneusi*, with decreased parasite shedding in the stool, after treatment with furazolidone in six patients with AIDS.13 The infection, however, was not eradicated by the schedules of treatment used, and two patients had clinical and parasitological relapse two months after treatment was discontinued.

A search for more lasting results led us to use a combination of furazolidone and albendazole to treat four AIDS patients with symptomatic *E. bieneusi* infection of the gut. The rationale of this approach lies in the fact that the mechanism of action of these drugs seems complementary, being directed at different metabolic pathways in the parasite. Furazolidone probably interferes with the synthesis of nucleic acids by an action on the Krebs cycle, while albendazole, which inhibits tubulin polymerisation into microtubules of parasites,14–16 may affect the precursors of polar tubes of *E. bieneusi*.

In this study our aim was to confirm the results obtained using furazolidone alone,13 and to evaluate the ability of combined furazolidone and albendazole to produce persistent clinical and parasitological remission without the need for maintenance treatment.

**Methods**

We enrolled four HIV positive drug misusing patients (three male, one female) with symptomatic *E. bieneusi* infection of the gut. The patients were aged between 31 and 35 years. All had AIDS at the time of study entry; according to the 1993 CDC revised classification system, two cases belonged to the C, stage, while the others to the B, stage. The mean CD4+T cell count was 7.7 × 10⁵/litre (range 4 to 11). All patients had chronic diarrhoea (for at least two months), with a range of two to five watery stools a day (mean four). Weight loss ranged between 3 and 8 kg (mean 5.5).
Stool were processed according to the methods of Weber et al and of Van Gool et al to detect microsporidia.17–19 The amount of spore shedding was evaluated by a semiquantitative criterion on 100 microscopic fields: spores were defined as very frequent if present in every field, frequent if present in more than 50 but fewer than 100 fields, rare if present in fewer than 50 fields, and very rare if sporadically present.

Before study entry, frequent to very frequent spores of microsporidia were present in stools of all patients. Stool samples were also examined for bacteria, Clostridium difficile toxin, mycobacteria, eggs and parasites, adenoviruses, and rotaviruses, with negative results.

Transmission electron microscopy (TEM) was performed on endoscopic biopsy specimens taken from the third part of duodenum before treatment. At least two samples from each patient were processed. Specimens were fixed with glutaraldehyde 2.5% in cacodylate buffer (pH 7.4) for three to four hours at room temperature, washed in the same buffer, and postfixed in osmium tetroxide in 1% Millonig buffer (SIC, Rome, Italy) for one hour at room temperature. After dehydration through graded acetone series, the specimens passed through propylene oxide and were then embedded in Epon 812. Semithin sections (3 µm) were cut, stained with toluidine blue–sodium tetraborate, and studied by light microscopy. About 100 ultrathin sections were obtained from all the selected specimens and were stained with uranyl acetate and alkaline bismuth subnitrate. For each section at least three random fields were examined by TEM. Care was taken to evaluate only areas away from the borders of the biopsy specimen to avoid traumatic artefact.

All patients underwent a baseline evaluation that included full blood cell count, urine analysis, electrolytes, liver function tests, and abdominal ultrasonography.

Combination treatment with furazolidone (100 mg tablet five times daily) and albendazole (400 mg tablet twice daily) was given orally to all the patients for 18 days. Written informed consent was obtained before treatment. No concomitant anti diarrhoeal drugs were allowed. Clinical assessment and haematological and liver function tests were monitored after 10 days and at the end of treatment. Adverse events were evaluated.

Three days after completion of treatment, upper endoscopy was performed in three patients who gave their consent. One of these patients also underwent endoscopy two months after discontinuation of treatment. In all cases, at least two biopsy specimens were taken from the third part of duodenum, and were processed as described above. The ultrathin sections obtained were examined by TEM by two pathologists blind to the patients’ treatment or clinical outcome.

In all patients spore shedding in the stool was monitored by Weber’s method at the end of treatment and monthly during follow up (one stool sample a day for three days). Daily stool frequency and body weight were charted, and the CD4+T cell count was repeated every four months after discontinuation of treatment. The mean duration of follow up was eight months (range four to 15).

A complete response was defined as cessation of diarrhoea (stool frequency less than twice a day), stabilisation of body weight, and a major decrease (or clearance) of spore shedding in the stools for more than three months. A partial response was defined as improvement in baseline stool frequency, with ongoing weight loss, and slight or no decrease in spore shedding in stool.

Results

CLINICAL RESPONSE

All patients showed a complete response, with remission of symptoms and a major decrease or absence of spore shedding in the stools from the time of completion of treatment. The drugs were well tolerated, although, probably as a side effect of furazolidone,20 there was a slight worsening of diarrhoea in all patients during treatment. This was promptly reversed when treatment was discontinued, and there were no alterations in the laboratory test results attributable to the drugs used.

Over the follow up period no patient had a relapse, either clinical or parasitological, despite the fact that no maintenance treatment was given and no improvement in CD4+T cell count was documented.

Figure 1 Microsporidian spores (stool specimen after treatment). Many spores are evident, almost all showing a pronounced red stained clot. A normal spore is seen (arrow). (Magnification ×795.)
Case 1 regained his preinfection body weight and was asymptomatic during four months of follow up, although very rare to frequent microsporidian spores, most of which were dysmorphous, were intermittently excreted in the stools. The patient later moved to another city and was lost to the follow up.

Case 2 was symptom-free over 15 months of follow up, and regained his preinfection body weight. He showed clearance of parasite in stool, with occasional shedding of very rare to frequent spores, most of which were dysmorphous.

Case 3 had six months of follow up showing parasite clearance in stool or intermittent shedding of very rare spores, most of which were dysmorphous. The patient regained his preinfection body weight and was asymptomatic until he died of *Rhodococcus equi* pneumonia and *Staphylococcus aureus* septicemia.

Case 4 had no diarrhoea during seven months of follow up, although there was intermittent shedding in the stools of very rare to very frequent spores, almost all being dysmorphous. The patient showed body weight increase, and had neither clinical nor parasitological relapse until his death from severe intestinal bleeding.

**Parasite changes in the stools**

Parasite changes were detected by Weber's stain in all patients' stools after treatment. In these cases a marked red stained clot was distinguishable within the spores (fig 1), and replaced the pinkish red belt-like stripe originally described by Weber *et al.*\(^1^\). The mean number of altered spores was 10 in each microscopic field (range 1–50).

Dysmorphous spores were intermittently shed in stool, and coexisted with normal spores with a mean ratio of 5:1. These spore changes seen by light microscopy were persistently detected during follow up in all the patients, and were identical to those described after treatment with furazolidone alone.\(^3\)

**Parasite damage in biopsy specimens**

Unaltered phases of the *E bieneusi* life cycle were found in all fields studied from biopsies.
taken before treatment (fig 2), and the parasites were present in almost all of the semi-thin and ultrathin sections obtained.

After treatment, ultrastructural changes at all stages of *E. bieneusi* were observed in the biopsy specimens, and were most pronounced in sporogonial plasmodia and spores. Most sporogonial plasmodia had disarranged nuclear chromatin, and many showed disruption of nuclear membranes, irregularity of nuclear profiles and diastasis between the nuclear membrane and the nucleoplasm (figs 3 and 4). Several electron-dense discs also failed to develop into polar tubes and appeared disorganised, deformed, disrupted, and pale (figs 3 and 4). Most spores were very electron-dense, and showed enlarged electron-lucent vacuoles (fig 5).

These changes were observed both in biopsy specimens obtained just after completion of treatment and two months later, and were similar to changes reported after furazolidone alone.13

There was a substantial decrease in microsporidia, documented by both light microscopy and TEM, in all biopsies taken either just after completion of treatment or two months later, and the parasites were found in fewer than half of all semi-thin and ultrathin sections obtained. A broken spore and a giant spore containing two electron-lucent vacuoles and multiple coils of the polar tube were also observed in biopsies taken after treatment (figs 6 and 7).

These alterations were not found after treatment with furazolidone alone.13 No abnormalities in host cell structures were seen in biopsy specimens obtained before and after treatment.

**Discussion**

Combination treatment with furazolidone and albendazole was associated with a complete response in four severely immunocompromised AIDS patients with symptomatic *E. bieneusi* infection.

All patients had long lasting symptomatic relief with a substantial decrease—or transient absence—of protozoan shedding in the stools, and regained their preinfection body weight. The regimen was well tolerated by all the patients, and there were no alterations in the laboratory test results attributable to the drugs used. During long term follow up no patient had a relapse, either clinical or parasitological, despite there being no documented improvement in CD4+T cell count and no maintenance treatment. Such a prolonged effect was not seen after treatment with furazolidone alone,13 nor has it been reported to date after any other treatment against *E. bieneusi*.

Combination treatment with furazolidone and albendazole resulted in persistent alterations in the parasite. Ultrastructural changes at all stages of *E. bieneusi* were documented not only in biopsy specimens taken at endoscopy just after completion of treatment, but also in biopsies obtained two months later. These changes were most pronounced in sporogonial plasmodia and spores, and were similar to changes observed after furazolidone alone, including osmiophilic spores with enlarged vacuoles as revealed in a retrospective TEM study.

A substantial decrease in microsporidia was a persistent feature of all biopsies obtained, either immediately after discontinuation of treatment or two months later. We also found both a broken spore and a giant spore, suggesting incomplete division of the sporonts. These findings are of interest as they were not observed after furazolidone alone,13 nor have they been reported with any other treatment, though giant spores have previously been found with albendazole treatment.11-12 Furthermore, dysmorphic spores were persistently
Combined furazolidone and albendazole for *E bieneusi*

... documented in all patients’ stool by Weber’s method after combination therapy, and were correlated to the post-treatment parasite alterations seen by TEM in biopsy specimens. These changes in faecal spores were identical to those previously described after furazolidone alone, and were not seen in our four patients before treatment. We hypothesise that these changes could derive from furazolidone mediated damage to the spore coat, with subsequent increasing permeability, as suggested by osmiophilic spores seen by TEM in biopsy specimens.

We are unable to explain why dysmorphic spores persisted for long periods in all the patients’ stools after combination treatment was discontinued. We can only hypothesise that this might have been caused by the persistence of genomic damage to the parasite induced by furazolidone and transmissible, as an inherited defect, to the progeny during reproduction. This hypothesis agrees with our TEM results of persistent alterations in *E bieneusi*, at all stages of the life cycle, in all biopsies obtained two months after stopping treatment.

Both the decrease of parasite load and the parasite damage seen in post-treatment biopsies may account for the decrease in parasite load and the spore changes persistently seen in stool after treatment. These findings are in agreement with a recent report that closely linked the quantitation of *E bieneusi* in tissue with quantitation in the stools, and may explain the long lasting symptomatic relief we observed during follow up in all the patients.

Our preliminary results suggest that combined furazolidone and albendazole have a direct action on *E bieneusi*, probably by inhibiting parasite multiplication, and may be effective in achieving persistent clinical and pathological remission even in patients with severe immunodeficiency. Whether our results can be interpreted as an enhancement of albendazole activity secondary to parasite damage caused by furazolidone is difficult to assess at this stage, although a complementary effect, as suggested by clinical and parasitological responses, seems probable.

This study confirms the results reported after furazolidone alone, and emphasises the importance of combining furazolidone with albendazole to achieve a substantial and persistent reduction in the parasites, avoiding the need for maintenance treatment. However, although this combination greatly reduced the numbers of microsporidia, it did not completely eradicate the infection as some parasites developed normally and gave rise to normal spores. Nevertheless, our study supports the efficacy and safety of a new drug regimen for the treatment of *E bieneusi* microsporidiosis.

The long lasting symptomatic relief observed after combined furazolidone and albendazole was correlated with the persistent decrease in parasite burden, both in the tissues and in the stools, and with the morphological changes of the protozoan life cycle.

The long term natural history of *E bieneusi* infection is not well understood, and spontaneous remission—as occurs with cryptosporidiosis—is quite often seen in clinical practice. Randomised controlled trials are required to validate the results of our uncontrolled pilot study and to dispel doubts about spontaneous remission or improvement resulting from the treatment of concomitant infections. These factors were unlikely to have been operative in our cases, however, since all the patients showed a pronounced response to the combination treatment, while no spontaneous remission, either clinical or parasitological, had been observed before. Moreover, to our knowledge, none of the drugs we used to treat concomitant infections (table 1) has any reported activity against *E bieneusi*.

We are indebted to Dr Esther Diana for constructive criticism and helpful comments in reviewing manuscript.

---

**Table 1 Concomitant infections**

<table>
<thead>
<tr>
<th>Case</th>
<th>Disease</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>Oral candidiasis</td>
<td>Fluconazole</td>
</tr>
<tr>
<td>3</td>
<td><em>Oesophageal candidiasis</em></td>
<td>Fluconazole</td>
</tr>
<tr>
<td>4</td>
<td><em>Rhodococcus equi</em> pneumonia</td>
<td>Vancomycin + rifampicin + clarithromycin</td>
</tr>
<tr>
<td>5</td>
<td><em>Staphylococcus aureus</em> septicemia</td>
<td>Vancomycin</td>
</tr>
<tr>
<td>6</td>
<td><em>Oesophageal candidiasis</em></td>
<td>Fluconazole</td>
</tr>
</tbody>
</table>

---


Royal College of Pathologists
Forthcoming Symposia

Transfusion Medicine Update
17–18 November 1998

Cytopathology Update
17 December 1998

What to do When the Cause of Death is in the Brain
27 January 1999

Antimicrobial Resistance: In Humans and Other Animals
17 February 1999

Cytokines and Chemokines in Disease
18 March 1999

Can’t Give a Cause of Death—Won’t Give a Cause of Death
22 April 1999

These meetings will be held at the Royal College of Pathologists, 2 Carlton House Terrace, London SW1Y 5AF and are open to members and non-members of the College.

Further details and application forms from the Scientific Meetings Officer, tel +44 (0)171 930 5862, ext 24/25; fax +44 (0)171 321 0523.